I agree. This reads well. There are so many things going on, and revenue seems to be gaining traction. Once it achieves CF+, will support their drug development program (much like CUV). With ~30ml in cash, and a current revenue run rate of ~16ml, at a 47ml EV, puts it on ~3 times revenue. This looks like good value for a unique offering company with lots of levers to the upside.
Ann: Q3 FY24 Quarterly Investor Presentation, page-3
-
- There are more pages in this discussion • 4 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MAP (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
18.5¢ |
Change
-0.005(2.63%) |
Mkt cap ! $82.85M | |||
| Open | High | Low | Value | Volume |
| 19.0¢ | 19.0¢ | 18.0¢ | $34.42K | 188.5K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 92380 | 18.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 19.0¢ | 32999 | 1 |
View Market Depth
| Last trade - 14.51pm 31/07/2024 (20 minute delay) ? |
| MAP (ASX) Chart |